Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | metabotropic glutamate receptor | 0.0175 | 0.0621 | 0.5392 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.1277 | 1 | 0.5 |
Echinococcus granulosus | metabotropic glutamate receptor 5 | 0.0257 | 0.1318 | 1 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.1277 | 1 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.1277 | 1 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0166 | 0.0547 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.1277 | 1 | 0.5 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0208 | 0.0908 | 1 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.1277 | 1 | 0.5 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0237 | 0.1151 | 1 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.1277 | 1 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0166 | 0.0547 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0166 | 0.0547 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.1277 | 1 | 0.5 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.0257 | 0.1318 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0257 | 0.1318 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0166 | 0.0547 | 0.5 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0189 | 0.0742 | 0.8166 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0166 | 0.0547 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (binding) | = 14.1 % | Inhibition of Trypanosoma brucei PDEB1 at 100 uM | ChEMBL. | 22370268 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.